KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio : Jefferies Starts Kronos Bio at Buy With $36 Price Target

11/03/2020 | 08:36am EDT


© MT Newswires 2020
All news about KRONOS BIO, INC.
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/12Kronos Bio to Feature Entospletinib, Lanraplenib Investigational Inhibitors at European..
MT
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/04KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/04Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
GL
05/04Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/21KRONOS BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/08Kronos Bio Says Preclinical Data Shows Potential for Its Treatment of Certain Cancer Ty..
MT
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -155 M - -
Net cash 2022 72,8 M - -
P/E ratio 2022 -1,31x
Yield 2022 -
Capitalization 213 M 213 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 96
Free-Float 85,5%
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,76 $
Average target price 29,50 $
Spread / Average Target 685%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-72.33%213
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524